Brief: Arctic Bioscience Says It Has Liquidity Giving Runway Into Q1
Oct 29 (Reuters) - Arctic Bioscience AS ABSA.OL :
* Q3 2024 OPERATIONAL UPDATE
* HAS AVAILABLE LIQUIDITY GIVING RUNWAY INTO Q1 2025
* WILL INCREASE FOCUS ON NUTRACEUTICAL BUSINESS
* AIMING FOR A TOTAL YEAR-OVER-YEAR REVENUE GROWTH IN 2024
OF
25-30 %
Source text: ID:nWkr4xRjwH
Further company coverage: ABSA.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Arctic Bioscience AS
See all newsNorway's Arctic Bioscience Q1 sales rise 78% to record on America boost
Brief: Arctic Bioscience Q1 Adjusted EBITDA NOK -6.5 Million
Norway's Arctic Bioscience 2025 revenue falls due to product recall impact
Brief: Arctic Bioscience Q3 Adjusted EBITDA NOK -7.8 Million
Brief: Arctic Bioscience H1 Adjusted EBITDA NOK -13.6 Million